Can we improve the identification of ventricular scar to guide substrate-based ventricular tachycardia ablation?

摘要

The use of implantable cardioverter defibrillators (ICDs) for the primary or secondary prevention of sudden cardiac death (SCD) has been a class I American College of Cardiology/American Heart Association/North American Society of Pacing and Electrophysiology guideline recommendation for more than a decade.1"3 Current practice guidelines are based on prospective multicenter clinical trials that demonstrated significant reductions in the risk of SCD in patients with heart failure (HF) of various etiologies.4"7 Approximately 20-35% of HF patients who receive an ICD for primary SCD prevention and up to 45% of HF patients who receive an ICD for secondary SCD prevention will receive an appropriate shock within 3 years of implantation.